140 results on '"Schessl J"'
Search Results
2. POS1229 DO MYOSITIS AUTOANTIBODIES PREDICT RESPONSE TO IVIG IN DERMATOMYOSITIS? A POST-HOC ANALYSIS OF THE PRODERM TRIAL
3. Muscle ultrasound in classic infantile and adult Pompe disease: A useful screening tool in adults but not in infants
4. OP0008 A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL OF IVIG 10% IN PATIENTS WITH DERMATOMYOSITIS. THE PRODERM STUDY: RESULTS ON EFFICACY AND SAFETY
5. Prospective study on anti-ganglioside antibodies in childhood Guillain-Barre syndrome
6. AUTOIMMUNE MYOPATHIES
7. Long-term efficiency of intravenously administered immunoglobulin in anti-Yo syndrome with paraneoplastic cerebellar degeneration
8. Aszites und Abmagerung bei intrakranieller Raumforderung
9. DO MYOSITIS AUTOANTIBODIES PREDICT RESPONSE TO IVIG IN DERMATOMYOSITIS? A POST-HOC ANALYSIS OF THE PRODERM TRIAL.
10. 169th ENMC International Workshop Rare Structural Congenital Myopathies 6–8 November 2009, Naarden, The Netherlands
11. EP 40. Gynecomastia – A sign of a neuromuscular disease?
12. New insights into the protein aggregation pathology in myotilinopathy by combined proteomic and immunolocalization analyses
13. Proteomic characterization of aggregate components in an intrafamilial variable FHL1opathy
14. Novel recessive myotilin mutation cause severe myofibrillar myopathy
15. Clinical variability in siblings with calpainopathy (LGMD2A)
16. G.P.151
17. G.P.148
18. A.P.5
19. A.P.1
20. Muscle MRI in FHL1-linked reducing body myopathy
21. Evaluation of standardized protein pattern of skeletal muscle fibers via laser microdissection
22. The C224W FHL1 mutation is causing a protein aggregation disorder of muscle: Two brothers revisited
23. Identification of FHL1 as a regulator of skeletal muscle mass: implications for human myopathy
24. G.P.123 Identification of molecular effects of FHL1 mutations on protein assembly in reducing body myopathy
25. P5.51 Evaluation of standardized protein pattern of skeletal muscle fibers via laser microdissection
26. P5.53 The C224W FHL1 mutation is causing a protein aggregation disorder of muscle: Two brothers revisited
27. P2.42 Cys150Arg FHL1 mutation in two brothers affected by the Emery-Dreifuss muscular dystrophy phenotype
28. Long-term efficiency of intravenously administered immunoglobulin in anti-Yo syndrome with paraneoplastic cerebellar degeneration
29. Familial Reducing Body Myopathy with Cytoplasmic Bodies and Rigid Spine Revisited: Identification of a Second LIM Domain Mutation in FHL1
30. G.P.5.10 Novel FHL1 mutation in familial mixed reducing body myopathy with rigid spine
31. G.P.13.04 In-frame deletion of the entire dystrophin rod domain prevents compensation by utrophin and causes an unusually severe muscular dystrophy
32. Proteomic identification of the LIM domain protein FHL1 as the gene-product mutated in reducing body myopathy
33. Treatment of Duchenne muscular dystrophy with cyclosporin A – A randomized, double-blind, placebo controlled trial
34. G.O.2 Proteomic identification of the LIM domain protein FHL1 as the gene-product mutated in reducing body myopathy
35. Role of GluR1 in Activity-Dependent Motor System Development
36. G.P.1.05 siRNA mediated allele specific selective silencing of a dominant negative COL6A3 mutation causing UCMD
37. C.P.2.04 Skipping of exon 16 in COL6A3 is a recurrent mutation causing severe congenital muscular dystrophy type Ullrich
38. G.P.4.14 Clinical variability in siblings with calpainopathy (LGMD2A)
39. Clinical Presentation and Course of Childhood Guillain-Barré Syndrome: A Prospective Multicentre Study
40. Clinical trial 'immunosuppressive treatment in Duchenne muscular dystrophy' – update
41. Neuronal plasticity II: modulation of cortical excitability
42. Clinical features of cardiomyopathy in muscular dystrophy Duchenne and Becker-Kiener
43. Neuronal plasticity I – maturation of cortical excitability
44. Off-label-use of botulinum toxin a (BTX A) in pediatric patients
45. Prospektive multizentrische Studie über vorausgehende Erkrankungen und über MHC Klasse I und Klasse II Polymorphismen beim kindlichen Guillain-Barré-Syndrom
46. G.P.148: FHL1 mutations are causing familial aortic and other arterial aneurysms with scapuloperoneal myopathy
47. G.P.151: Loss of FHL1 function impairs motility and causes myopathy in vivo
48. A.P.1: Proteomic analysis in 72 myofibrillar myopathy (MFM) patients identifies new disease-relevant proteins accumulating in aggregates and reveals subtype-specific proteomic profiles
49. A.P.5: Novel recessive myotilin mutation cause severe myofibrillar myopathy
50. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.